Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
ConclusionIn adults with newly diagnosed Ph + ALL, first-line treatment with ponatinib was associated with better outcomes than first-line treatment with imatinib.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Clinical Trials | Dexamethasone | Drugs & Pharmacology | Gleevec | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants